Finding ways to overcome resistance to a specific cancer treatment
Official title: Targeting PGC1β/PPARγ axis for overcoming acquired resistant to third generation EGFR-TKIs
Funded at Emory University · NIH-10991730 · Data updated 2026-11-12
This study is looking at ways to help lung cancer patients who aren't responding well to certain treatments by exploring how specific proteins might be causing this resistance, with the hope of finding better therapies that could help them stay in remission longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $484,479 |
| NIH project number | 5R01CA281148-02 |
| Project ID | NIH-10991730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with lung cancer who have EGFR activating mutations and have experienced resistance to third generation EGFR-TKIs.
✕Less likely to help
Patients without EGFR mutations or those who have not been treated with EGFR-TKIs may not benefit from this research.
What this research studies
This research investigates how to overcome resistance to third generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), which are used to treat patients with certain types of lung cancer. The study focuses on the roles of specific proteins, PGC1β and PPARγ, that may contribute to this resistance. By analyzing cancer cells that have developed resistance, the researchers aim to identify new strategies to enhance the effectiveness of these treatments. Patients may benefit from improved therapies that could lead to longer remission periods.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients who have developed resistance to current therapies.
How similar studies have gone: Previous research has shown promise in targeting similar pathways to overcome treatment resistance in cancer, indicating that this approach may be viable.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Sun, Shi-Yong — Emory University
- Study coordinator: Sun, Shi-Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.